Secondary hyperparathyroidism (SHPT) refers to one of the serious, common, and progressive complication associated with Chronic Kidney Disease (CKD) that is mainly characterized by high levels of parathyroid hormone, mineral metabolism abnormalities, and parathyroid gland hyperplasia. Failing kidneys are unable to convert Vitamin A to its active form as they do not adequately excrete phosphate resulting into formation of insoluble calcium phosphate by the body thus, leading to secondary hyperparathyroidism. The common signs and symptoms of the disease includes bone and joint pain as well as limb deformities. The disturbances caused in the secondary hyperparathyroidism patients may lead to poor quality of life and short life expectancy. Treatment for SHPT involves surgical operation or consumption of prescribed drugs that helps to maintain the level of parathyroid hormone, calcium, and phosphorous within the accepted targeted areas. According to the U.S. Food & Drug Administration (FDA) 2012, Secondary hyperparathyroidism is a serious chronic condition that affects a high percentage of patients receiving kidney dialysis. In case of prognosis, if the SHPT is left untreated, the disease progresses to tertiary hyperparathyroidism and is then associated with hypercalcemia. According to the National Institute of Diabetes & Digestive & Kidney Diseases, the two prime reasons resulting in chronic kidney disease are diabetes and high blood pressure. Patients suffering from CKD, due to one of the reasons, if remain undetected can progress to irreversible kidney failure.
Secondary Hyperparathyroidism Treatment Market: Market Dynamics
Rising incidence of chronic kidney diseases is one of the major factors responsible for growth of the global secondary hyperparathyroidism treatment market. According to Centers of Disease Control & Prevention (CDC) 2017, 30 million people or 15% of the U.S. adults are estimated to have chronic kidney disease, out of which 48% suffer severely with reduced kidney function, however, are not aware of having a CKD. Moreover, according to the National Kidney Foundation 2016, 10% of the population across the world are affected with chronic kidney diseases. Additionally, extensive research in the field of nephrology to come up with new drugs and therapies for treatment of secondary hyperparathyroidism is responsible for fueling growth of the market. For instance, Sanofi SA’s Hectorol capsules is undergoing Phase 3 clinical trials to evaluate the safety and efficacy of this medication in reducing the level of secondary hyperparathyroidism in pediatric patients with chronic kidney diseases at stage 3 and 4. The drug is expected to complete its study in December 2017, and be commercially available in market. However, side effects usually associated with secondary hyperparathyroidism treatment such as muscle spasm, diarrhea, and vomiting may cause hindrance to growth of the market.
Secondary Hyperparathyroidism Treatment Market: Regional Insights
On the basis of region, the global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global secondary hyperparathyroidism treatment market, owing to increasing research and development of novel therapies and potential drugs for secondary hyperparathyroidism as well as high prevalence of chronic kidney disease. According to the Centers of Disease Control & Prevention (CDC), in 2014, 118,000 people in the U.S. started treatment for ESRD, and 662,000 were living on chronic dialysis. Furthermore, Europe is expected to be the second-largest contributor in the secondary hyperparathyroidism treatment market, in terms of revenue and is expected to gain significant traction in the near future. This is owing to launch of new drugs and therapies, to combat secondary hyperparathyroidism as well as presence of significant population suffering from the disease in this region. For instance, in December 2016, Amgen’s drug etecalcetide (Parsabiv), received marketing approval in Europe by the European Commission for treatment of secondary hyperparathyroidism in adult patients with chronic kidney diseases. Furthermore, Asia Pacific is expected to be the fastest growing region, owing to regional companies conducting clinical trials for launch of new drugs. For instance, Kyowa Hakko Kirin China Pharmaceutical Co., Ltd is under Phase 4 clinical trial to determine the safety and efficacy of its new lead compound Cinacalet for treatment of patients suffering with mild to moderate SHPT and expected to be launched in the market by April 2019.
Secondary Hyperparathyroidism Treatment Market: Competitive Analysis
Key players operating in the global secondary hyperparathyroidism treatment market include AbbVie, Inc., Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG, Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc., Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing on innovation and new product development, to maintain their position in the market and enhance their share. For instance, in June 2016, OPKO Health introduced Rayaldee (calcifediol) for the treatment of SHPT in adults with stage 3 or 4 of chronic kidney disease.
Secondary Hyperparathyroidism Treatment Market: Market Taxonomy
The global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented on the basis of drug class and distribution channel.
On the basis of drug class, the global secondary hyperparathyroidism treatment market is segmented into:
- Vitamin D Derivatives
- Phosphate Binders
- Calcium-Based Binders
- Non-Calcium Based Binders
On the basis of distribution channel, the global secondary hyperparathyroidism treatment market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies